RecruitingRecruiting
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
NCT05567198 · National Institutes of Health Clinical Center (CC)
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Efficacy of Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
About this study
Study Description: SLE patients with life-threatening lupus manifestations are often treated with cyclophosphamide (CYC), which has known cytotoxic effects on ovarian reserve. Co-administration of Gonadotropinreleasing hormone agonist (GnRHa) is suggested to protect ovaries from the cytotoxic effects of CYC but there is lack of data to support this. We hypothesize that the co-administration of a GnRH agonist for the duration of CYC therapy will exert protective effects on ovarian reserve and function in SLE females. We plan to do a patient survey and a retrospective data collection to compare ovarian function in subjects who received CYC with GnRHa to those who received CYC without GnRHa.
Objectives:
Primary Objective: Determine the effectiveness of GnRH-a in preventing primary ovarian insufficiency (POI) in female SLE patients getting cyclophosphamide treatment.
Secondary Objectives: Determine the effects of SLE disease activity, damage accrual, cumulative dose of cyclophosphamide and other demographic and clinical variables in preventing primary ovarian insufficiency.
Eligibility criteria
* ELIGIBILITY CRITERIA:
* INCLUSION CRITERIA: Group 1: SLE patients receiving CYC alone
SLE females \<40 years at the beginning of CYC treatment without GnRH-a cotreatment.
-EXCLUSION CRITERIA: Group 1: SLE patients receiving CYC alone
Females \>40 years at the beginning of CYC treatment; any females with a prior history of reproductive disorders, infertility, or untreated sexually transmitted infections (STIs).
-INCLUSION CRITERIA: Group 2: SLE patients receiving both CYC and leuprolide acetate (GnRH-a). Leuprolide acetate was injected at a dose of either 3.75 mg/month or 11.25mg/every 3 months.
SLE females \<40 years at the beginning of CYC treatment with GnRH-a cotreatment.
-EXCLUSION CRITERIA: Group 2: SLE patients receiving both CYC and leuprolide acetate (GnRH-a). Leuprolide acetate was injected at a dose of either 3.75 mg/month or 11.25mg/every 3 months.
Females \>40 years at the beginning of CYC treatment; any females with a prior history of reproductive disorders, infertility, or untreated STIs.
-Group: Control subjects.
Age-matched female SLE patients without a history of reproductive disorders, infertility, or untreated STIs, who have not received CYC either with or without GnRH-a.
Study design
Enrollment target: 100 participants
Age groups: adult, older_adult
Timeline
Starts: 2023-03-03
Estimated completion: 2027-05-31
Last updated: 2026-11-10
Primary outcomes
- • POI (End of study)
Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · nih
Contacts & investigators
ContactSarfaraz A Hasni, M.D. · contact · hasnisa@mail.nih.gov · (301) 451-1599
InvestigatorSarfaraz A Hasni, M.D. · principal_investigator, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
All locations (1)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Recruiting
Bethesda, Maryland, United States